Tal Patalon

Dr. Tal Patalon

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 November 2021 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
MLMatan Levine-Tiefenbrun
Matan Levine-Tiefenbrun
IYIdan Yelin
Idan Yelin
HAHillel Alapi
Hillel Alapi
RKRachel Katz
Rachel Katz
EHEsma Herzel
Esma Herzel
RKRoy Kishony
Roy Kishony

4 November 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
BMBarak Mizrahi
Barak Mizrahi
RLRoni Lotan
Roni Lotan
NKNir Kalkstein
Nir Kalkstein
APAsaf Peretz
Asaf Peretz
GPGalit Perez
Galit Perez
TPTal Patalon
Tal Patalon
The short-term effectiveness of a two-dose regimen of the BioNTech/Pfizer mRNA BNT162b2 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine was widely demonstrated. However, long term effectiveness is still unknown. Leveraging the centralized computerized database of Maccabi Healthcare Services (MHS), we assessed the correlation between time-from-vaccine and incidence of breakthrough infection between June 1 and July 27, the date of analysis. After controlling for potential confounders as age and comorbidities, we found a significant 1.51 fold (95% CI, 1.38–1.66) increased risk for infection for early vaccinees compared to those vaccinated later that was similar across all ages groups. The increased risk reached 2.26- fold (95% CI, 1.80–3.01) when comparing those who were vaccinated in January to those vaccinated in April. This preliminary finding of vaccine waning as a factor of time from vaccince should prompt further investigations into long-term protection against different strains.

12 November 2021 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
AYAdam Yala
Adam Yala
PMPeter G. Mikhael
Peter G. Mikhael
FSFredrik Strand
Fredrik Strand
Gigin LinGigin Lin
Gigin Lin
SSSiddharth Satuluru
Siddharth Satuluru
RBRegina Barzilay
Regina Barzilay
PURPOSE: Accurate risk assessment is essential for the success of population screening programs in breast cancer. Models with high sensitivity and specificity would enable programs to target more elaborate screening efforts to high-risk populations, while minimizing overtreatment for the rest. Artificial intelligence (AI)-based risk models have demonstrated a significant advance over risk models used today in clinical practice. However, the responsible deployment of novel AI requires careful validation across diverse populations. To this end, we validate our AI-based model, Mirai, across globally diverse screening populations. METHODS: We collected screening mammograms and pathology-confirmed breast cancer outcomes from Massachusetts General Hospital, USA; Novant, USA; Emory, USA; Maccabi-Assuta, Israel; Karolinska, Sweden; Chang Gung Memorial Hospital, Taiwan; and Barretos, Brazil. We evaluated Uno's concordance index for Mirai in predicting risk of breast cancer at one to five years from the mammogram. RESULTS: A total of 128,793 mammograms from 62,185 patients were collected across the seven sites, of which 3,815 were followed by a cancer diagnosis within 5 years. Mirai obtained concordance indices of 0.75 (95% CI, 0.72 to 0.78), 0.75 (95% CI, 0.70 to 0.80), 0.77 (95% CI, 0.75 to 0.79), 0.77 (95% CI, 0.73 to 0.81), 0.81 (95% CI, 0.79 to 0.82), 0.79 (95% CI, 0.76 to 0.83), and 0.84 (95% CI, 0.81 to 0.88) at Massachusetts General Hospital, Novant, Emory, Maccabi-Assuta, Karolinska, Chang Gung Memorial Hospital, and Barretos, respectively. CONCLUSION: Mirai, a mammography-based risk model, maintained its accuracy across globally diverse test sets from seven hospitals across five countries. This is the broadest validation to date of an AI-based breast cancer model and suggests that the technology can offer broad and equitable improvements in care.

9 June 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
TPTal Patalon
Tal Patalon
YSYaki Saciuk
Yaki Saciuk
APAsaf Peretz
Asaf Peretz
GPGalit Perez
Galit Perez
YLYoav Lurie
Yoav Lurie
SGSivan Gazit
Sivan Gazit
The duration of protection of the third (booster) dose of the BioNTech/Pfizer BNT162b2 mRNA Coronavirus Disease 2019 vaccine has been the subject of recent investigations, as global discussions around the necessity and effectiveness of a fourth dose are already underway. By conducting a retrospective study implementing a test-negative case-control design, analyzing 546,924 PCR tests performed throughout January 2022 by 389,265 persons who received at least two doses, we find that the effectiveness in each month-since-vaccination decreases significantly. Compared to those vaccinated five months prior to the outcome period, on August 2021, relative protection against infection waned from 53.4% a month after vaccination to 16.5% three months after vaccination. These results suggest that there is a significant waning of vaccine effectiveness against the Omicron variant of the third dose of the BNT162b2 vaccine within a few months after administration. Additional information could assist to comprehensively estimate the effectiveness of the three-dose-strategy.

27 January 2022 in Science
Verified
Journal Article
Open access
OPOttavia Prunas
Ottavia Prunas
JWJoshua Warren
Joshua Warren
FCForrest W. Crawford
Forrest W. Crawford
SGSivan Gazit
Sivan Gazit
TPTal Patalon
Tal Patalon
VPVirginia E. Pitzer
Virginia E. Pitzer
The effectiveness of vaccines against COVID-19 on the individual level is well established. However, few studies have examined vaccine effectiveness against transmission. We used a chain binomial model to estimate the effectiveness of vaccination with BNT162b2 [Pfizer-BioNTech messenger RNA (mRNA)-based vaccine] against household transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in Israel before and after emergence of the B.1.617.2 (Delta) variant. Vaccination reduced susceptibility to infection by 89.4% [95% confidence interval (CI): 88.7 to 90.0%], whereas vaccine effectiveness against infectiousness given infection was 23.0% (95% CI: −11.3 to 46.7%) during days 10 to 90 after the second dose, before 1 June 2021. Total vaccine effectiveness was 91.8% (95% CI: 88.1 to 94.3%). However, vaccine effectiveness is reduced over time as a result of the combined effect of waning of immunity and emergence of the Delta variant.

10 June 2021 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
OMOren Milman
Oren Milman
IYIdan Yelin
Idan Yelin
NANoga Aharony
Noga Aharony
RKRachel Katz
Rachel Katz
EHEsma Herzel
Esma Herzel
RKRoy Kishony
Roy Kishony